Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Squamous Intraepithelial Lesions 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1HIV Seropositivity 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 6Cisplatin 5Radiotherapy 4Paclitaxel 3Nivolumab 3lenvatinib 2Specimen Handling 2Platinum 2Papillomavirus Vaccines 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Gemcitabine 2Carboplatin 2CTLA-4 Antigen 2Bleomycin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1rocakinogene sifuplasmid 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cemiplimab 1belzutifan 1antineoplaston AS 2-1 1antineoplaston A10 1alovudine 1aldesleukin 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vulvar Neoplasms × VGX-3100 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡